[PDF] Top 20 Ibrutinib for B cell malignancies
Has 10000 "Ibrutinib for B cell malignancies" found on our website. Below are the top 20 most common "Ibrutinib for B cell malignancies".
Ibrutinib for B cell malignancies
... ceived ibrutinib, the first-in-class, oral covalent inhibitor of BTK; Among these 85 patients, 51 received 420 mg and 34 received 840 ...by ibrutinib from bone marrow, lymph nodes, and spleen where stromal ... See full document
7
Irreversible dual inhibitory mode: the novel Btk inhibitor PLS- 123 demonstrates promising anti-tumor activity in human B-cell lymphoma
... The B-cell receptor (BCR) signaling pathway has gained significant attention as a therapeutic target in B-cell ...inhibitor ibrutinib, have demonstrated notable therapeutic effects in ... See full document
15
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
... neoplastic B cells, which implies that clinically effective inhibitors, such as ibrutinib and idelalisib, do not chiefly target BCR signaling in the literal sense, but different (as yet incompletely ... See full document
14
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma
... of B-cell ...of ibrutinib in relapsed DLBCL ...to ibrutinib [2, 6, ...to ibrutinib eventually relapse, underscoring the need for developing new target agents and combination treat- ... See full document
16
Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
... of B-cell malignancies on the B-cell receptor (BCR) signaling path- way has led to the development of novel orally-bioavailable small-molecule inhibitors of several kinases downstream ... See full document
6
Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib
... in B cell trafficking and homing are rapidly spreading in the landscape of therapeutic options in B cell malignancies, in particular in CLL and MCL settings where current standard ... See full document
13
Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment
... especially ibrutinib (PCI-32765), have shown great anti-lymphoma activities in preclinical study and clinical trials ...[18-20]. Ibrutinib is an irrevers- ible and selective Btk inhibitor, which binds ... See full document
9
Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia
... trials, Ibrutinib is the most advanced molecule for the treatment of B-cell malignancies ...[1]. Ibrutinib is an orally available, selective and irreversible inhibitor of BTK that ... See full document
16
Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200
... Immune checkpoint blockade has unquestionably trans- formed the field of cancer immunotherapy producing some quite remarkable and long-lasting effects, particularly in melanoma and some hematopoietic tumors. However, it ... See full document
9
XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy
... Activated B-cell like; AML: Acute myeloid leukemia; APC: Adenomatous polyposis coli; BCR: B-cell receptor; BD: Binding domain; BRCA1: Breast cancer 1; BRD4: Bromodomain-containing protein 4; ... See full document
13
Potential added value of a RT-qPCR method of SOX 11 expression, in the context of a multidisciplinary diagnostic assessment of B cell malignancies
... normal B-cells, correlated with IGHV mutational status in MCL, makes SOX11 a poten- tial biomarker for CCND1-negative MCL, both at diag- nosis and in the evaluation of minimal residual disease ... See full document
6
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
... in B cell ...of cell therapies is related to the low tumor burden, preemptive therapy should be performed upon the detection of MRD via molecular or immunophenotypic methods ...CAR-T cell ... See full document
8
New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies
... malignant B cell lines and kill autologous lymphoma B cells, indicating that D393-CD20—derived epitopes are naturally processed and presented on tumor cells ... See full document
15
Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies
... The human cancer cell lines, SKM-1, Ramos and Hs 505.T were purchased from the American Type Culture Collection (ATCC) (Manassas, VA, USA). The FLT3-ITD- expressing line, MV4-11, was provided by Dr. Anthony Letai, ... See full document
11
Aberrant Activation of NF-κB Signalling in Aggressive Lymphoid Malignancies
... naïve B-cell repertoire comparable to their wild-type counterparts ...during B-cell ...to B cells, since GC formation was strongly impaired in conditional Rel knockout mice with ... See full document
21
<p>Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis</p>
... reported B cell aplasia. B cell aplasia is an on- target off tumour effect due to response in normal cells with the CAR-targeted ...like B cell aplasia, inducible caspase 9, a ... See full document
10
Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies
... Notes: (A) Biodistribution of cy5.5-anti-cD20 NPs (0.3 nmol cy5.5, 125 mg NPs) injected intravenously via the tail vein in a mouse model subcutaneously transplanted with the CLL cell line MEC1 (leukemic mouse ... See full document
11
Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors
... for B-cell lymphocyte malignancies targeting CD19 places it in a rapidly growing field in cancer immunotherapy for both hematological and solid ... See full document
12
The MYC /miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potential
... different cell types and is essential for many developmental and pathogenic ...promoting cell survival, rapid cell proliferation, and increased ...hematopoietic malignancies including diffuse ... See full document
12
Universal CARs, universal T cells, and universal CAR T cells
... T cell products have been approved for clinical treatment of B lymphoid malignancies [27, ...T cell paradigm is a significant limiting factor for large-scale deployment of the CAR technology ... See full document
9
Related subjects